18F meta fluorobenzylguanidine - Illumina Radiopharmaceuticals
Alternative Names: 18F-meta-fluorobenzylguanidine - Illumina Radiopharmaceuticals; 18F-mFBG; 18F-mFBG - Illumina Radiopharmaceuticals; Florbenguane F-18; IRP101; Meta-fluorobenzylguanidine - Illumina Radiopharmaceuticals; Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agentLatest Information Update: 16 Feb 2024
Price :
$50 *
At a glance
- Originator Illumina Radiopharmaceuticals
- Class Contrast media; Diagnostic agents; Fluorine radioisotopes; Fluorobenzenes; Guanidines; Imaging agents; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Emission-computed tomography enhancers; Magnetic resonance imaging enhancers; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Neuroblastoma
- Preclinical Cardiovascular disorders
Most Recent Events
- 16 Feb 2024 Innervate Radiopharmaceuticals plans a phase II trial for Neuroblastoma, Pheochromocytoma and Paraganglioma in USA in July 2024 (NCT06233903)
- 01 Feb 2024 Innervate Radiopharmaceuticals completes a phase-III trial in Neuroblastoma (Diagnosis, (In adults, In children, In the elderly, In adolescents) in USA (unspecified route) (NCT04724369)
- 05 Feb 2021 Chemical structure information added